Literature DB >> 26763959

Effects of Treated versus Untreated Polystyrene on Caspofungin In Vitro Activity against Candida Species.

Annette W Fothergill1, Dora I McCarthy1, Mohammad T Albataineh1, Carmita Sanders1, Maria McElmeel1, Nathan P Wiederhold2.   

Abstract

Significant interlaboratory variability is observed in testing the caspofungin susceptibility of Candida species by both the CLSI and EUCAST broth microdilution methodologies. We evaluated the influence of treated versus untreated polystyrene microtiter trays on caspofungin MICs using 209 isolates of four Candida species, including 16 C. albicans and 11 C. glabrata isolates with defined FKS mutations. Caspofungin MICs were also determined using the commercially available YeastOne and Etest assays and 102 isolates. All C. glabrata isolates had caspofungin MICs of ≥0.5 μg/ml, the clinical breakpoint for caspofungin resistance in this species, measured using trays made of treated polystyrene, regardless of the FKS status. In contrast, susceptible isolates could readily be distinguished from resistant/non-wild-type isolates when caspofungin MICs were measured using untreated polystyrene trays and both the YeastOne and Etest assays. Similar results were also observed for C. krusei isolates, as all isolates had caspofungin MICs above the threshold for resistance measured using treated polystyrene trays. In contrast, C. albicans isolates could be correctly identified as susceptible or resistant when caspofungin MICs were measured with treated or untreated trays and with the YeastOne and Etest assays. MICs falsely elevated above the resistance breakpoint were also not observed for C. tropicalis isolates. These results demonstrated that the use of treated polystyrene may be one factor that leads to falsely elevated caspofungin in vitro susceptibility results and that this may also be a greater issue for some Candida species than for others.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26763959      PMCID: PMC4767986          DOI: 10.1128/JCM.02659-15

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  13 in total

1.  Colistin susceptibility testing: time for a review.

Authors:  Mahableshwar Albur; Alan Noel; Karen Bowker; Alasdair Macgowan
Journal:  J Antimicrob Chemother       Date:  2013-12-29       Impact factor: 5.790

2.  Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?

Authors:  A Espinel-Ingroff; M C Arendrup; M A Pfaller; L X Bonfietti; B Bustamante; E Canton; E Chryssanthou; M Cuenca-Estrella; E Dannaoui; A Fothergill; J Fuller; P Gaustad; G M Gonzalez; J Guarro; C Lass-Flörl; S R Lockhart; J F Meis; C B Moore; L Ostrosky-Zeichner; T Pelaez; S R B S Pukinskas; G St-Germain; M W Szeszs; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2013-09-09       Impact factor: 5.191

3.  Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment.

Authors:  John D Cleary; Guillermo Garcia-Effron; Stanley W Chapman; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2008-03-31       Impact factor: 5.191

4.  Use of anidulafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 4,290 clinical isolates of Candida by using CLSI methods and interpretive criteria.

Authors:  Michael A Pfaller; Daniel J Diekema; Ronald N Jones; Mariana Castanheira
Journal:  J Clin Microbiol       Date:  2014-06-20       Impact factor: 5.948

5.  Use of a surfactant (polysorbate 80) to improve MIC susceptibility testing results for polymyxin B and colistin.

Authors:  Helio S Sader; Paul R Rhomberg; Robert K Flamm; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2012-10-25       Impact factor: 2.803

6.  Real-world experience with echinocandin MICs against Candida species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates.

Authors:  Gregory A Eschenauer; M Hong Nguyen; Shmuel Shoham; Jose A Vazquez; Arthur J Morris; William A Pasculle; Christine J Kubin; Kenneth P Klinker; Peggy L Carver; Kimberly E Hanson; Sharon Chen; Simon W Lam; Brian A Potoski; Lloyd G Clarke; Ryan K Shields; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2014-01-06       Impact factor: 5.191

7.  Use of micafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 3,764 clinical isolates of Candida by use of CLSI methods and interpretive criteria.

Authors:  Michael A Pfaller; Shawn A Messer; Daniel J Diekema; Ronald N Jones; Mariana Castanheira
Journal:  J Clin Microbiol       Date:  2013-10-23       Impact factor: 5.948

8.  The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata.

Authors:  Ryan K Shields; M Hong Nguyen; Ellen G Press; Andrea L Kwa; Shaoji Cheng; Chen Du; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2012-07-02       Impact factor: 5.191

9.  Colistin MIC variability by method for contemporary clinical isolates of multidrug-resistant Gram-negative bacilli.

Authors:  Janet A Hindler; Romney M Humphries
Journal:  J Clin Microbiol       Date:  2013-03-13       Impact factor: 5.948

10.  Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint.

Authors:  Guillermo Garcia-Effron; Samuel Lee; Steven Park; John D Cleary; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2009-06-22       Impact factor: 5.191

View more
  7 in total

1.  EUCAST Reference Testing of Rezafungin Susceptibility and Impact of Choice of Plastic Plates.

Authors:  Maiken Cavling Arendrup; Karin Meinike Jørgensen; Rasmus Krøger Hare; Manuel Cuenca-Estrella; Oscar Zaragoza
Journal:  Antimicrob Agents Chemother       Date:  2019-08-23       Impact factor: 5.191

Review 2.  Echinocandin Resistance in Candida Species: a Review of Recent Developments.

Authors:  Nathan P Wiederhold
Journal:  Curr Infect Dis Rep       Date:  2016-12       Impact factor: 3.725

3.  EUCAST Determination of Olorofim (F901318) Susceptibility of Mold Species, Method Validation, and MICs.

Authors:  Karin Meinike Jørgensen; Karen M T Astvad; Rasmus Krøger Hare; Maiken Cavling Arendrup
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

4.  Hot topics in antifungal susceptibility testing: A new drug, a bad bug, sweeping caspofungin testing under the rug, and solving the ECV shrug.

Authors:  Shawn R Lockhart; Elizabeth L Berkow
Journal:  Clin Microbiol Newsl       Date:  2016-07

5.  In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae.

Authors:  Zoltán Tóth; Lajos Forgács; Jeffrey B Locke; Gábor Kardos; Fruzsina Nagy; Renátó Kovács; Adrien Szekely; Andrew M Borman; László Majoros
Journal:  J Antimicrob Chemother       Date:  2019-12-01       Impact factor: 5.790

6.  Azole-Resistant Aspergillus fumigatus Clinical Isolate Screening in Azole-Containing Agar Plates (EUCAST E.Def 10.1): Low Impact of Plastic Trays Used and Poor Performance in Cryptic Species.

Authors:  Julia Serrano-Lobo; Ana Gómez; Belén Rodríguez-Sánchez; Patricia Muñoz; Pilar Escribano; Jesús Guinea
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

Review 7.  Antimicrobial Susceptibility Testing of Antimicrobial Peptides to Better Predict Efficacy.

Authors:  Derry K Mercer; Marcelo D T Torres; Searle S Duay; Emma Lovie; Laura Simpson; Maren von Köckritz-Blickwede; Cesar de la Fuente-Nunez; Deborah A O'Neil; Alfredo M Angeles-Boza
Journal:  Front Cell Infect Microbiol       Date:  2020-07-07       Impact factor: 5.293

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.